Advertisement
Screener

OCUGEN, INC. (OCGN) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

OCUGEN, INC. Financing Cash Flow

OCUGEN, INC. (OCGN) reported Financing Cash Flow of $115.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06

  • OCUGEN, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $80.37M, a 131650.82% increase year-over-year.
  • OCUGEN, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $34.98M.
  • OCUGEN, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.00K, a 99.99% decline year-over-year.
  • OCUGEN, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $18.51M, a 46.79% decline year-over-year.
  • OCUGEN, INC. net cash provided by (used in) financing activities for fiscal 2025 was $17.33M, a 73.28% decline from fiscal 2024.
  • OCUGEN, INC. net cash provided by (used in) financing activities for fiscal 2024 was $64.86M, a 210.61% increase from fiscal 2023.
  • OCUGEN, INC. net cash provided by (used in) financing activities for fiscal 2023 was $20.88M, a 64.89% decline from fiscal 2022.
  • OCUGEN, INC. net cash provided by (used in) financing activities for fiscal 2022 was $59.48M, a 50.72% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 9 month as first filedNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 12 month as first filed
2026-06-30$80.37M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$115.35M
10-Q · filed 2026-08-06
$115.35M
derived: sum of 3 quarters · filed 2026-08-06
$133.86M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$34.98M
10-Q · filed 2026-05-08
$34.99M
derived: sum of 2 quarters · filed 2026-05-08
$53.50M
derived: sum of 3 quarters · filed 2026-05-08
$53.56M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$2.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$18.51M
derived: sum of 2 quarters · filed 2026-03-04
$18.57M
derived: sum of 3 quarters · filed 2026-08-06
$17.33M
10-K · filed 2026-03-04
2025-09-30$18.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$18.57M
derived: sum of 2 quarters · filed 2026-08-06
$17.33M
10-Q · filed 2025-11-05
$47.50M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$61.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$1.18M
10-Q · filed 2026-08-06
$28.99M
derived: sum of 3 quarters · filed 2026-08-06
$63.77M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$1.25M
10-Q · filed 2026-05-08
$28.93M
derived: sum of 2 quarters · filed 2026-05-08
$63.71M
derived: sum of 3 quarters · filed 2026-05-08
$63.76M
derived: sum of 4 quarters · filed 2026-05-08
2024-12-31$30.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$64.96M
derived: sum of 2 quarters · filed 2026-03-04
$65.00M
derived: sum of 3 quarters · filed 2026-03-04
$64.86M
10-K · filed 2026-03-04
2024-09-30$34.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$34.83M
derived: sum of 2 quarters · filed 2025-11-05
$34.69M
10-Q · filed 2025-11-05
$34.70M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$45.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04
-$100.00K
10-Q · filed 2025-08-04
-$84.00K
derived: sum of 3 quarters · filed 2025-08-04
-$119.00K
derived: sum of 4 quarters · filed 2025-08-04
2024-03-31-$145.00K
10-Q · filed 2025-05-09
-$129.00K
derived: sum of 2 quarters · filed 2025-05-09
-$164.00K
derived: sum of 3 quarters · filed 2025-05-09
$15.24M
derived: sum of 4 quarters · filed 2025-05-09
2023-12-31$16.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05
-$19.00K
derived: sum of 2 quarters · filed 2025-03-05
$15.38M
derived: sum of 3 quarters · filed 2025-03-05
$20.88M
10-K · filed 2025-03-05
2023-09-30-$35.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$15.37M
derived: sum of 2 quarters · filed 2024-11-14
$20.86M
10-Q · filed 2024-11-14
$29.04M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$15.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$20.90M
10-Q · filed 2024-08-08
$29.07M
derived: sum of 3 quarters · filed 2024-08-08
$30.04M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$5.50M
10-Q · filed 2024-05-14
$13.67M
derived: sum of 2 quarters · filed 2024-05-14
$14.63M
derived: sum of 3 quarters · filed 2024-05-14
$14.87M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31$8.18M
derived: 10-K 12 month − 10-K 9 month · filed 2024-04-16
$9.14M
derived: sum of 2 quarters · filed 2024-04-16
$9.37M
derived: sum of 3 quarters · filed 2024-04-16
$59.48M
10-K · filed 2024-04-16
2022-09-30$962.00K
derived: 10-K 9 month − 10-K 6 month · filed 2024-04-16
$1.20M
derived: sum of 2 quarters · filed 2024-04-16
$51.30M
10-K · filed 2024-04-16
$51.91M
derived: sum of 4 quarters · filed 2024-04-16
2022-06-30$236.00K
derived: 10-K 6 month − 10-K 3 month · filed 2024-04-16
$50.34M
10-K · filed 2024-04-16
$50.94M
derived: sum of 3 quarters · filed 2024-04-16
$51.05M
derived: sum of 4 quarters · filed 2024-04-16
2022-03-31$50.10M
10-K · filed 2024-04-16
$50.71M
derived: sum of 2 quarters · filed 2024-04-16
$50.82M
derived: sum of 3 quarters · filed 2024-04-16
$144.48M
derived: sum of 4 quarters · filed 2024-04-16
2021-12-31$605.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$715.00K
derived: sum of 2 quarters · filed 2023-02-28
$94.38M
derived: sum of 3 quarters · filed 2023-02-28
$120.68M
10-K · filed 2023-02-28
2021-09-30$110.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$93.77M
derived: sum of 2 quarters · filed 2022-11-08
$120.07M
10-Q · filed 2022-11-08
$129.54M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$93.66M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05
$119.96M
10-Q · filed 2022-08-05
$129.43M
derived: sum of 3 quarters · filed 2022-08-05
$136.24M
derived: sum of 4 quarters · filed 2022-08-05
2021-03-31$26.30M
10-Q · filed 2022-05-06
$35.76M
derived: sum of 2 quarters · filed 2022-05-06
$42.58M
derived: sum of 3 quarters · filed 2022-05-06
$57.42M
derived: sum of 4 quarters · filed 2022-05-06
2020-12-31$9.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$16.28M
derived: sum of 2 quarters · filed 2022-02-28
$31.12M
derived: sum of 3 quarters · filed 2022-02-28
$31.61M
10-K · filed 2022-02-28
$31.61M
10-K · filed 2021-03-19
2020-09-30$6.81M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
$21.66M
derived: sum of 2 quarters · filed 2021-11-09
$22.14M
10-Q · filed 2021-11-09
$22.14M
10-Q · filed 2020-11-06
$23.05M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$14.84M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06
$15.33M
10-Q · filed 2021-08-06
$15.33M
10-Q · filed 2020-08-14
$16.24M
derived: sum of 3 quarters · filed 2022-02-28
$35.18M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$488.00K
10-Q · filed 2021-05-07
$488.30K
10-Q · filed 2020-05-08
$1.40M
derived: sum of 2 quarters · filed 2022-02-28
$20.34M
derived: sum of 3 quarters · filed 2022-02-28
$24.20M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$907.13K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$19.85M
derived: sum of 2 quarters · filed 2022-02-28
$23.71M
derived: sum of 3 quarters · filed 2022-02-28
$25.07M
10-K · filed 2022-02-28
$25.07M
10-K · filed 2020-03-27
2019-09-30$18.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06
$22.80M
derived: sum of 2 quarters · filed 2020-11-06
$24.16M
10-Q · filed 2020-11-06
$26.09M
derived: sum of 4 quarters · filed 2020-11-06
2019-06-30$3.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14
$5.21M
10-Q · filed 2020-08-14
-$1.45M
10-Q · filed 2019-08-09
$7.14M
derived: sum of 3 quarters · filed 2020-08-14
$6.44M
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31$1.36M
10-Q · filed 2020-05-08
$326.00K
10-Q · filed 2019-05-15
$3.29M
derived: sum of 2 quarters · filed 2020-05-08
$2.58M
derived: sum of 3 quarters · filed 2020-05-08
$3.05M
derived: sum of 4 quarters · filed 2020-05-08
2018-12-31$1.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27
$1.22M
derived: sum of 2 quarters · filed 2020-03-27
$1.69M
derived: sum of 3 quarters · filed 2020-03-27
$7.18M
10-K · filed 2020-03-27
$25.35M
10-K · filed 2019-03-22
2018-09-30-$706.99K
derived: 10-Q 9 month − 8-K/A 6 month · filed 2019-11-12
-$240.96K
derived: sum of 2 quarters · filed 2019-11-12
$5.25M
10-Q · filed 2019-11-12
$7.99M
10-Q · filed 2018-11-08
$5.11M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$466.03K
derived: 8-K/A 6 month − 10-Q 3 month · filed 2019-10-07
$5.96M
8-K/A · filed 2019-10-07
$5.45M
10-Q · filed 2018-08-09
$5.82M
derived: sum of 3 quarters · filed 2019-10-07
$5.68M
derived: sum of 4 quarters · filed 2019-10-07
2018-03-31$5.50M
10-Q · filed 2019-05-15
$5.35M
derived: sum of 2 quarters · filed 2019-05-15
$5.21M
derived: sum of 3 quarters · filed 2019-05-15
2017-12-31-$145.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22
-$286.00K
derived: sum of 2 quarters · filed 2019-03-22
-$577.00K
10-K · filed 2019-03-22
2017-09-30-$141.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$432.00K
10-Q · filed 2018-11-08
2017-06-30-$291.00K
10-Q · filed 2018-08-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
AGENUS INC (AGEN)United States$0.383B1.41
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Surrozen, Inc./DE (SRZN)United States$0.395B